Gilead Sciences (GILD) is Trading Near the Value of the HIV Opportunity, Jefferies Sees Good Risk/Reward
Tweet Send to a Friend
Jefferies analyst Michael Yee reiterated a Buy rating and $80.00 price target on Gilead Sciences (NASDAQ: GILD) seeing good risk ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
